Biogen Sinks Despite Raft of Analyst Upgrades

One day after flying sky high, Biogen (NASDAQ:BIIB) stock quickly obeyed gravity by falling marginally on Tuesday.

Interestingly, this came on a day when several analysts raised their price targets and/or recommendations on the stock. This was entirely expected, after the Food and Drug Administration (FDA) approved the company's aducanumab on Monday.